Baxter International has acquired Baxa, a US-based developer of pharmacy technology, for a cash consideration of $380m.
Subscribe to our email newsletter
Baxa is known for developing pharmacy technology to improve the efficiency and safety of oral and IV dose preparation and delivery.
Baxter Medical Products business president Robert Davis said the transaction will allow Baxter to provide a broader range of solutions for the safe preparation and delivery of IV medications.
"We believe Baxa’s expertise in safely preparing IV and oral liquid medications, and their shared commitment toward improving patient care through innovative drug preparation and delivery technology will benefit patients around the world," Davis added.